questionsmedicales.fr
Acides nucléiques, nucléotides et nucléosides
Nucléotides
Ribonucléotides
Nucléotides uridyliques
Uridine diphosphate
Uridine diphosphate : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Carence en nucléotides
Tests biochimiques
Tests enzymatiques
Chromatographie
Fatigue
Troubles neurologiques
Marqueurs biologiques
Enzymes
Symptômes
5
Fatigue
Troubles cognitifs
Système nerveux
Troubles neurologiques
Douleurs musculaires
Métabolisme énergétique
Troubles de l'humeur
Carence en nucléotides
Anomalies cutanées
Carence en nucléotides
Prévention
5
Prévention
Alimentation équilibrée
Suppléments
Régime alimentaire
Groupes à risque
Troubles métaboliques
Habitudes de vie
Exercice
Conseils nutritionnels
Nutritionniste
Traitements
5
Suppléments
Modifications alimentaires
Thérapies alternatives
Nutrition
Alimentation
Acides nucléiques
Traitements spécifiques
Troubles métaboliques
Complications
5
Complications neurologiques
Complications métaboliques
Développement cognitif
Enfants
Maladies chroniques
Carence en nucléotides
Maladies héréditaires
Métabolisme
Troubles immunitaires
Infections
Facteurs de risque
5
Facteurs de risque
Régimes alimentaires
Âge
Carence en nucléotides
Maladies génétiques
Synthèse
Habitudes alimentaires
Carence en nucléotides
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate : Questions médicales les plus fréquentes",
"headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Nucléotides uridyliques",
"url": "https://questionsmedicales.fr/mesh/D014500",
"about": {
"@type": "MedicalCondition",
"name": "Nucléotides uridyliques",
"code": {
"@type": "MedicalCode",
"code": "D014500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate ose",
"alternateName": "Uridine Diphosphate Sugars",
"url": "https://questionsmedicales.fr/mesh/D014539",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate ose",
"code": {
"@type": "MedicalCode",
"code": "D014539",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylgalactosamine",
"alternateName": "Uridine Diphosphate N-Acetylgalactosamine",
"url": "https://questionsmedicales.fr/mesh/D014536",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylgalactosamine",
"code": {
"@type": "MedicalCode",
"code": "D014536",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylglucosamine",
"alternateName": "Uridine Diphosphate N-Acetylglucosamine",
"url": "https://questionsmedicales.fr/mesh/D014537",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylglucosamine",
"code": {
"@type": "MedicalCode",
"code": "D014537",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate N-acétylmuramique",
"alternateName": "Uridine Diphosphate N-Acetylmuramic Acid",
"url": "https://questionsmedicales.fr/mesh/D014538",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate N-acétylmuramique",
"code": {
"@type": "MedicalCode",
"code": "D014538",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate galactose",
"alternateName": "Uridine Diphosphate Galactose",
"url": "https://questionsmedicales.fr/mesh/D014531",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate galactose",
"code": {
"@type": "MedicalCode",
"code": "D014531",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate glucose",
"alternateName": "Uridine Diphosphate Glucose",
"url": "https://questionsmedicales.fr/mesh/D014532",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate glucose",
"code": {
"@type": "MedicalCode",
"code": "D014532",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate glucuronique",
"alternateName": "Uridine Diphosphate Glucuronic Acid",
"url": "https://questionsmedicales.fr/mesh/D014535",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate glucuronique",
"code": {
"@type": "MedicalCode",
"code": "D014535",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate xylose",
"alternateName": "Uridine Diphosphate Xylose",
"url": "https://questionsmedicales.fr/mesh/D014540",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate xylose",
"code": {
"@type": "MedicalCode",
"code": "D014540",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.800"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate",
"alternateName": "Uridine Diphosphate",
"code": {
"@type": "MedicalCode",
"code": "D014530",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Takayuki Matsumoto",
"url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Kumiko Taguchi",
"url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan."
}
},
{
"@type": "Person",
"name": "Tsuneo Kobayashi",
"url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Rafal Jonczyk",
"url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
},
{
"@type": "Person",
"name": "Thomas Hoffmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Immunophenotyping of pulmonary sarcomatoid carcinoma.",
"datePublished": "2022-10-20",
"url": "https://questionsmedicales.fr/article/36341325",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.976739"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immune infiltration and immunophenotyping in atrial fibrillation.",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36602538",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/aging.204470"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunophenotypic characterization of acute leukemias in Bahia, Brazil.",
"datePublished": "2023-01-06",
"url": "https://questionsmedicales.fr/article/36629681",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31744/einstein_journal/2023AO0117"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Immunophenotypic Profile of Healthy Human Bone Marrow.",
"datePublished": "2023-06-04",
"url": "https://questionsmedicales.fr/article/37481314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cll.2023.04.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Describing IgA Myeloma: An Immunophenotypic and Molecular Approach.",
"datePublished": "2022-08-01",
"url": "https://questionsmedicales.fr/article/35882000",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides nucléiques, nucléotides et nucléosides",
"item": "https://questionsmedicales.fr/mesh/D009706"
},
{
"@type": "ListItem",
"position": 3,
"name": "Nucléotides",
"item": "https://questionsmedicales.fr/mesh/D009711"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ribonucléotides",
"item": "https://questionsmedicales.fr/mesh/D012265"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nucléotides uridyliques",
"item": "https://questionsmedicales.fr/mesh/D014500"
},
{
"@type": "ListItem",
"position": 6,
"name": "Uridine diphosphate",
"item": "https://questionsmedicales.fr/mesh/D014530"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Uridine diphosphate - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Uridine diphosphate",
"description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Immunophenotyping#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Uridine diphosphate",
"description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Immunophenotyping#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Uridine diphosphate",
"description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Immunophenotyping#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Uridine diphosphate",
"description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Immunophenotyping#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Uridine diphosphate",
"description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Immunophenotyping#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Uridine diphosphate",
"description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Immunophenotyping#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en UDP ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'UDP ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il être mesuré dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème d'UDP ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en UDP ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs."
}
},
{
"@type": "Question",
"name": "L'UDP affecte-t-il le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "L'UDP influence-t-il l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à l'UDP ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes."
}
},
{
"@type": "Question",
"name": "Comment prévenir une carence en UDP ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence."
}
},
{
"@type": "Question",
"name": "Les suppléments sont-ils nécessaires pour l'UDP ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque pour l'UDP ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles l'UDP ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels existent-ils pour l'UDP ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté."
}
},
{
"@type": "Question",
"name": "Comment traiter une carence en UDP ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à l'UDP ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives pour l'UDP ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des traitements spécifiques existent-ils pour l'UDP ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une carence en UDP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il affecter le développement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants."
}
},
{
"@type": "Question",
"name": "Des maladies chroniques sont-elles liées à l'UDP ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP."
}
},
{
"@type": "Question",
"name": "L'UDP est-il impliqué dans des maladies héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'UDP ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'UDP ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter l'UDP ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques influencent-elles l'UDP ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires jouent-elles un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp.
Publications dans "Uridine diphosphate" :
3 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan.
Publications dans "Uridine diphosphate" :
3 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany wilfried.schwab@tum.de.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, Changchun 130021, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, Changchun 130021, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, Changchun 130021, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
The Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng 475004, China. Electronic address: zhaoyuan@henu.edu.cn.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Agronomy College, Sichuan Agricultural University, Chengdu 611130, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo, 142-8501, Japan.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo, 142-8501, Japan.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo, 142-8501, Japan.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Department of Chemistry, The Scripps Research Institute, Jupiter, FL, United States.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Publications dans "Uridine diphosphate" :
Previous studies have suggested that patients with pulmonary sarcomatoid carcinoma (PSC)may benefit from immune checkpoint inhibitors (ICIs); however, relevant data are lacking. This study aimed to es...
A retrospective analysis of pathologically confirmed PSC cases from two centers was performed from January 2009 to May 2021. According to the infiltration of CD8+ T cells in different spatial regions,...
A total of 32 patients with PSC were included in the final analysis. Of these patients, 65.6% (21/32), 15.6% (5/32), and 18.8% (6/32) were classified as immune-inflamed, immune-excluded, and immune-de...
Patients with PSC are characterized by immune-inflamed type and type I (PD-L1+/CD8+, adaptive immune resistance), explaining the intrinsic reasons for their high response rate to immunotherapy....
Atrial fibrillation (AF) is a relatively common arrhythmia in clinical practice. Although significant progress has been achieved in the treatment of AF and its associated complications, research on AF...
To characterize the immunophenotypic profile of acute leukemias in the population of the state of Bahia, Brazil....
This is a descriptive, retrospective study. From 2014 to 2018, 796 new cases of acute leukemia were evaluated. The data were obtained from analysis of reports and records of tests performed by flow cy...
Most cases were diagnosed as acute myeloid leukemia and 42.7% as acute lymphoblastic leukemia. Significant differences were found in expression of markers in acute leukemias when age groups were compa...
Significant differences were found as to several antigens when comparing adults and children, and these findings may contribute to future studies correlating the phenotypic profile to genetic characte...
Flow cytometry enables multiparametric characterization of hematopoietic cell immunophenotype. Deviations from normal immunophenotypic patterns comprise a cardinal feature of many hematopoietic neopla...
Plasma cell myeloma (PCM) is defined as a clonal disease of terminally differentiated plasma cells that secrete immunoglobulin. The biologic underpinnings of IgA-type multiple myeloma's (IgAMM) aggres...
ASD reconstructions are a major, sterile traumatic insult, likely causing perturbations to the immune systems. The immune response to surgery is associated with outcomes. The purpose of this study was...
Consecutive patients undergoing ASD surgery were approached and enrolled. Peripheral blood was drawn before incision, 4 h after, and 24 h after incision. Blood was stabilized and comprehensive flow cy...
Thirteen patients were enrolled; 11(85%) F, 65.4 years (± 7.5), surgical duration 418 ± 83 min, EBL 1928 ± 1253 mL. Hierarchical clustering and PCA found consistent time from incision-dependent change...
Despite surgery and patient heterogeneity, we identified an immune signature associated with the sterile trauma of ASD surgery. Circulating leukocyte populations change in composition and signaling pr...
We aimed to provide an autophagy-related signature to seek immunophenotyping biomarkers in osteoarthritis (OA)....
Microarray expression profiling of OA subchondral bone samples and screening of an autophagy database for autophagy-related differentially expressed genes (au-DEGs) between OA and normal samples were ...
We screened 754 au-DEGs between OA and control samples, and co-expression networks were constructed using au-DEGs. Three OA-related autophagy hub genes (HSPA5, HSP90AA1, and ITPKB) were identified. Ba...
Three autophagy-related markers of OA were identified using bioinformatics methods, and these markers may be useful for the autophagy-related immunophenotyping of OA. The present data may facilitate t...
Prompt diagnosis of acute promyelocytic leukemia (APL) is critical for patient care. In this study, we aimed to characterize the immunophenotype of APL and explore immunophenotypic difference between ...
Eighty-five cases were collected, including 47 APL, 26 NPM1-mutated acute myeloid leukemia (AML) and 12 KMT2A-rearranged AML with an APL-like immunophenotype. Immunophenotypes were analyzed using flow...
APL showed four distinct patterns (designated a-d) based on CD45/SSC plots. Blasts in patterns a-c showed high side scatter, whereas blasts in pattern d had low side scatter and were located in the tr...
APL and its immunophenotypic mimics share some immunophenotypic similarities but can be distinguished by CD2, CD13, CD34, CD64, and MPO....
Acute myeloid leukemia (AML) with RAM immunophenotype is a distinct subtype of AML, as described by the Children's Oncology Group (COG), with characteristic morphological and immunophenotypic properti...
Seven cases with the characteristic RAM immunophenotype were identified in this retrospective analysis of newly diagnosed pediatric AML cases from January 2019 to December 2021. Herein, we have critic...
Of 302 cases of pediatric AML (age <18 years), seven cases (2.3%) with the distinct RAM phenotype were observed, with age ranging from 9 months to 5 years. Two patients were misdiagnosed earlier as sm...
AML with RAM immunophenotype, a distinct form of pediatric AML with a poor prognosis, may pose a diagnostic challenge if presented as a soft tissue mass. A comprehensive immunophenotypic evaluation, i...
Tγδ large granular lymphocyte leukemia (Tγδ LGLL) is a rare lymphoproliferative disease, scantily described in literature. A deep-analysis, in an initial cohort of 9 Tγδ LGLL compared to 23 healthy co...